Oligonucleotides: Promising Therapeutics With Significant Challenges
contributed by Corden Pharma |
In recent years, interest in oligonucleotide therapeutics has resurged, as new approaches, clinical applications, advances in delivery, and a deeper biological understanding of these compounds emerge. However, expectations have been largely unfulfilled, as only three oligonucleotide drugs have been approved by the FDA for use in the United States as of August 2017.
Today, close to 200 clinical trials are registered at ClinicalTrials. gov in 2017, and as of 2016, more than 10,000 patients will have been treated with oligonucleotide drugs.1 Further, more than 120 companies globally are active in therapeutic oligo development,2 with the global market for nucleic acid aptamers expected to reach about $5.4 billion by 2019.
As a result, Contract Development & Manufacturing Organizations (CDMOs) with expertise in this field, such as CordenPharma, are experiencing increased demand for these services. However, while the outlook is positive, significant challenges remain.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.